SCHEMBL699042

SCHEMBL699042

COC(=O)[C@@H]1C[C@@H](S(=O)(=O)CC2CC2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.39
NR1H3 Q13133 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTPN1 P18031 1/20 0.39
CTSL P07711 2/20 0.38
CTSB P07858 2/20 0.38
CTSS P25774 2/20 0.38
CTSK P43235 2/20 0.38
MMP2 P08253 1/20 0.35
ANPEP P15144 1/20 0.35
CYP3A4 P08684 3/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
P2RX3 P56373 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700342 0.88 SMN1; SMN2 (0.43) NR1H2SMN1; SMN2CTSLCTSBCTSS
SCHEMBL30571887 0.83 NR1H2 (0.42) NR1H2NR1H3SMN1; SMN2PTPN1CTSL
SCHEMBL699391 0.82 NR1H2 (0.46) NR1H2NR1H3PTPN1CTSLCTSB
SCHEMBL30571858 0.81 NR1H2 (0.38) NR1H2NR1H3SMN1; SMN2PTPN1CTSL
SCHEMBL31441847 0.81 NR1H2 (0.45) NR1H2NR1H3SMN1; SMN2PTPN1CTSL
SCHEMBL2105252 0.81 MMP2 (0.39) CTSSMMP2ANPEPCYP3A4KDM4E
SCHEMBL697247 0.81 MMP2 (0.39) CTSSMMP2ANPEPCYP3A4KDM4E
SCHEMBL2106096 0.79 CTSS (0.51) CTSLCTSBCTSS
SCHEMBL6122335 0.79 MMP2 (0.43) NR1H2NR1H3SMN1; SMN2PTPN1MMP2
SCHEMBL19853313 0.79 MMP2 (0.43) NR1H2NR1H3SMN1; SMN2PTPN1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 NR1H2 1251/4885NR1H3 1203/4885SMN1; SMN2 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.